18-Methylaminocoronaridine
18-Methylaminocoronaridine (18-MAC) is a synthetic derivative of the naturally occurring alkaloid ibogaine. It belongs to the class of iboga alkaloids and has been studied for its potential therapeutic effects, particularly in the treatment of substance use disorders.
Chemical Structure and Properties[edit | edit source]
18-Methylaminocoronaridine is structurally related to ibogaine, with the primary difference being the addition of a methylamino group. This modification is believed to influence its pharmacological profile and potentially reduce some of the adverse effects associated with ibogaine.
Pharmacology[edit | edit source]
18-MAC acts on multiple neurotransmitter systems, including the dopamine, serotonin, and glutamate systems. It is thought to exert its effects by modulating these neurotransmitter pathways, which are implicated in addiction and neuroplasticity.
Mechanism of Action[edit | edit source]
The exact mechanism of action of 18-MAC is not fully understood. However, it is believed to interact with NMDA receptors, sigma receptors, and nicotinic acetylcholine receptors. These interactions may contribute to its potential anti-addictive properties.
Therapeutic Potential[edit | edit source]
Research on 18-Methylaminocoronaridine has primarily focused on its potential use in treating substance use disorders, including opioid addiction, cocaine addiction, and alcohol dependence. Preclinical studies have shown promising results, but clinical trials are necessary to establish its efficacy and safety in humans.
Side Effects and Safety[edit | edit source]
As with other iboga alkaloids, there are concerns about the safety profile of 18-MAC. Potential side effects may include cardiotoxicity, neurotoxicity, and hallucinogenic effects. Further research is needed to fully understand the risk-benefit profile of this compound.
Legal Status[edit | edit source]
The legal status of 18-Methylaminocoronaridine varies by country. In some jurisdictions, it may be classified under the same regulations as ibogaine, while in others, it may not be specifically regulated.
See Also[edit | edit source]
- Ibogaine
- Substance use disorder
- Neurotransmitter
- NMDA receptor
- Sigma receptor
- Nicotinic acetylcholine receptor
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD